1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 11-20 of 31 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2000A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemiaBranford, S.; Rudzi, Z.; Hughes, T.
2003Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHDRoberts, M.; Dyson, P.; Rawling, C.; Thorp, D.; Rawling, T.; White, D.; Horvath, N.; Bardy, P.; Hui, C.; Dart, G.; To, L.; Hughes, T.
2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.
2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
2003Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRHui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2009Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMuller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
2009Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A TrialApperley, J.; Cortes, J.; Kim, D.; Roy, L.; Roboz, G.; Rosti, G.; Bullorsky, E.; Abruzzese, E.; Hochhaus, A.; Heim, D.; De Souza, C.; Larson, R.; Lipton, J.; Khoury, J.; Kim, H.; Sillaber, C.; Hughes, T.; Erben, P.; Tornout, J.; Stone, R.

Discover